PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
A) Phase II: Early viral responses to triazavirin In hospitalised patients with mild-moderate
COVID-19, in addition to standard of care therapy, treatment with triazavirin 250mg three
times daily for five days, the slope of increase of the Ct values of serial nasopharyngeal
swabs to 12 days after initiation of treatment will be ≥24% higher than in hospitalised
patients receiving standard of care treatment only.
B) Phase III: Efficacy of triazavirin to improve clinical outcomes In hospitalised patients
with mild-moderate laboratory proven COVID-19, in addition to standard of care therapy,
treatment with triazavirin 250mg three times daily for five days will reduce a composite
outcome - death; ICU admission or mechanical ventilation; or prolonged duration of admission-
by ≥29% when compared to the composite outcome in hospitalised patients receiving standard of
care therapy only.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Fatima Mayat Wits Health Consortium (Pty) Ltd
Collaborators:
Perinatal HIV Research Unit of the University of the Witwatersrand PharmaCentrix (Pty) Ltd